Navigation Links
Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Date:4/7/2009

DENVER, April 7 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO), has been selected as one of the presenting companies at the Company Showcase during BIOZONA 2009 - Arizona's Annual Bioscience Industry Conference at the Sheraton Phoenix Downtown on April 7th in Phoenix, Arizona.

Matthew B. Wiener, PharmD, COO and Founder of Pharmatech Oncology, will present during the first session of the conference. The presentation will cover topics including: the science, business and markets on which the company is based, recent accomplishments, and strategic partnerships.

Dr. Wiener will focus on the many accomplishments for Pharmatech Oncology in cancer clinical trials utilizing the Just-In-Time (JIT) enrollment methodology. The aim of the Just-In-Time program is to shorten the time to enroll cancer patients into clinical trials and also expand the number of patients being offered trials. "Pharmatech Oncology is honored to be selected from a large number of applicants to be one of eighteen companies presenting at this distinguished BIOZONA event. We anticipate great exposure for our Just-In-Time clinical trial program, as we feel it is revolutionizing the enrollment process of adult cancer patients into clinical trials," states Dr. Wiener. For further information about BIOZONA 2009, please visit the event web site at http://www.azbio.org/Biozona2009.asp.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. With Data Management as a separate business entity, it allows for management of data for other types
'/>"/>

SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
2. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
3. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
4. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
7. Pharmatech 2.0: Introducing Pharmatech Oncology
8. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Announces Third Quarter 2008 Results
11. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead ... to protect the Orange County, Texas area from future storm surge flooding, such ... in determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic ...
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, ... good progress in evaluating the full range of capabilities of its unique cache ... stem cells perform the day-to-day renewal and repair of normal tissues and organs. ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... Texas, Dec. 21 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... investigational new drug (IND) application to the U.S. ... drug candidate for managing,gastrointestinal symptoms associated with carcinoid ... is planned as a double-blind, randomized,placebo-controlled, ascending single-dose ...
... MALVERN, Pa., Dec. 21 Solstice Neurosciences, Inc.,("Solstice") ... President and,Chief Executive Officer. He will also continue ... Mr. Smith brings unique specialty pharmaceutical industry ... in providing guidance,leadership, and strategies for growth as ...
... ROCK, Colo., Dec. 20 AspenBio Pharma,Inc. (Nasdaq: ... to the,development of novel drugs and diagnostics for ... into securities purchase agreements in,connection with a private ... Under the terms of the agreement, AspenBio will ...
Cached Biology Technology:Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome 2Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome 3Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc. 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 3
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... 16, 2013 With its fingerprint-identity sensor, Apple,s new ... mobile devices.  Unfortunately, it didn,t take long for hackers ... 5S, but software from an upstate New ... – safeguards users, devices against such vulnerabilities. ...
... NEW YORK , Oct. 17, 2013 /PRNewswire-iReach/ -- ... and personalized medicine, is pleased to announce the deployment of ... based on its proprietary cloud-based biomedical engine, Cliniscan ... Cliniscan TM , the ...
... Babcock Genetics, Inc., a worldwide supplier of swine genetics, announces ... genetic program available to swine producers. "Babcock ... offer a higher level of profitability to our customers." said ... are maximizing genetic improvement by selecting lines that best complement ...
Cached Biology News:NexID Biometrics: The Solution to Spoofing Mobile Biometrics 2NexID Biometrics: The Solution to Spoofing Mobile Biometrics 3Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support 2Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support 3
8.1.1...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
... and efficient purification of DNA and oligonucleotides ... by gravity flow.Prepacked with Sephadex G-25 DNA ... CG/ICP Biocide.Available in three sizes depending on ... ml (NAP-10) or 2.5 ml (NAP-25).Useful for ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Biology Products: